Translational Stroke Research Using a Rabbit Embolic Stroke Model: A Correlative Analysis Hypothesis for Novel Therapy Development

摘要: Alteplase (tissue plasminogen activator, tPA) is currently the only FDA-approved treatment that can be given to acute ischemic stroke (AIS) patients if present within 3 h of an stroke. After 14 years alteplase clinical research, evidence now suggests therapeutic window expanded 4.5 h, but this not formally approved by FDA. Even though there remains a significant risk intracerebral hemorrhage associated with administration, increased chance favorable outcome tPA treatment. Over last 30 years, use preclinical models has assisted search for new effective treatments stroke, been difficulty translation efficacy from animals humans. Current research focuses on development and potentially useful thrombolytics, neuroprotective agents, devices which are also being tested in trials. One model particular, rabbit small clot embolic (RSCEM) was developed test efficacy, used gain FDA approval Correlative analyses existing translational studies trials indicate ratio (ARR) 2.43-3 between RSCEM AIS patients. In conclusion, as tool gauge potential treatments.